Enhanced liver Fibrosis® test predicts liver-related outcomes in the general population

Pimpin, 2018, Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies, J Hepatol, 69, 718, 10.1016/j.jhep.2018.05.011 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Karlsen, 2022, The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality, Lancet, 399, 61, 10.1016/S0140-6736(21)01701-3 Holmer, 2018, Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries, Liver Int, 38, 2082, 10.1111/liv.13751 Sayiner, 2019, Disease burden of hepatocellular carcinoma: a global perspective, Dig Dis Sci, 64, 910, 10.1007/s10620-019-05537-2 Antonio, 2017, Mortality from cirrhosis and hepatocellular carcinoma in Western Europe over the last 40 years, Liver Int, 37, 1193, 10.1111/liv.13371 Männistö, 2021, Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease, Liver Int, 41, 2590, 10.1111/liv.15004 Ratib, 2014, 1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998–2009: a large population study, J Hepatol, 60, 282, 10.1016/j.jhep.2013.09.027 Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 Dulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002/hep.29085 Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368 Hagström, 2017, Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, J Hepatol, 67, 1265, 10.1016/j.jhep.2017.07.027 Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study, Gastroenterology, 155, 443, 10.1053/j.gastro.2018.04.034 Lackner, 2019, Fibrosis and alcohol-related liver disease, J Hepatol, 70, 294, 10.1016/j.jhep.2018.12.003 Rasmussen, 2021, Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease, J Hepatol, 75, 1017, 10.1016/j.jhep.2021.05.037 Tian, 2020, Complications after percutaneous ultrasound-guided liver biopsy: a systematic review and meta-analysis of a population of more than 12,000 patients from 51 cohort studies, J Ultrasound Med, 39, 1355, 10.1002/jum.15229 Berzigotti, 2021, EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update, J Hepatol, 75, 659, 10.1016/j.jhep.2021.05.025 Rosenberg, 2004, Serum markers detect the presence of liver fibrosis: a cohort study, Gastroenterology, 127, 1704, 10.1053/j.gastro.2004.08.052 Guha, 2008, Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers, Hepatology, 47, 455, 10.1002/hep.21984 Vali, 2020, Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis, J Hepatol, 73, 252, 10.1016/j.jhep.2020.03.036 Thiele, 2018, Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease, Gastroenterology, 154, 1369, 10.1053/j.gastro.2018.01.005 Parkes, 2010, Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease, Gut, 59, 1245, 10.1136/gut.2009.203166 Day, 2019, Derivation and performance of standardized Enhanced Liver Fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis, J Appl Lab Med, 3, 815, 10.1373/jalm.2018.027359 Irvine, 2016, The Enhanced Liver Fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease, Liver Int, 36, 370, 10.1111/liv.12896 Are, 2021, Enhanced Liver Fibrosis Score can be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis, Clin Gastroenterol Hepatol, 19, 1292, 10.1016/j.cgh.2020.06.070 Sanyal, 2019, The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials, Hepatology, 70, 1913, 10.1002/hep.30664 Vesterhus, 2015, Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis, Hepatology, 62, 188, 10.1002/hep.27825 Vries, 2016, Enhanced Liver Fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-center study Fujinaga, 2021, Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis, Medicine (Baltimore), 100, 10.1097/MD.0000000000027403 Mayo, 2008, Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay, Hepatology, 48, 1549, 10.1002/hep.22517 Glen, 2016, Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance, BMJ, 354, i4428, 10.1136/bmj.i4428 Aromaa, 2004 2022 2021, Classification and diagnosis of diabetes: standards of medical care in diabetes—2021, Diabetes Care, 44, S15, 10.2337/dc21-S002 Alberti, 2009, Harmonizing the metabolic syndrome, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 Bedogni, 2006, The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population, BMC Gastroenterol, 6, 33, 10.1186/1471-230X-6-33 Puigvehi, 2016, Diagnostic accuracy of the Enhanced Liver Fibrosis (ELF®) score using HCV-infected serum samples cryopreserved for up to 25 years, PLoS One, 11, 10.1371/journal.pone.0164883 Kennedy, 2017, The Enhanced Liver Fibrosis (ELF) panel: analyte stability under common sample storage conditions used in clinical practice, J Appl Lab Med, 1, 720, 10.1373/jalm.2016.022806 Sund, 2012, Quality of the Finnish hospital discharge register: a systematic review, Scand J Public Health, 40, 505, 10.1177/1403494812456637 Hagström, 2021, Administrative coding in electronic health care record-based research of NAFLD: an Expert Panel Consensus Statement, Hepatology, 74, 474, 10.1002/hep.31726 Rahman, 2017, Review and evaluation of performance measures for survival prediction models in external validation settings, BMC Med Res Methodol, 17, 60, 10.1186/s12874-017-0336-2 Blanche, 2019, The c-index is not proper for the evaluation of $t$-year predicted risks, Biostatistics, 20, 347, 10.1093/biostatistics/kxy006 Choodari-Oskooei, 2012, A simulation study of predictive ability measures in a survival model I: explained variation measures, Stat Med, 31, 2627, 10.1002/sim.4242 Forrest, 2021, The diagnostic and prognostic significance of liver histology in alcoholic hepatitis, Aliment Pharmacol Ther, 53, 426, 10.1111/apt.16157 Younossi, 2019, Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Hepatology, 69, 2672, 10.1002/hep.30251 Guillaume, 2019, Direct comparison of the specialised blood fibrosis tests FibroMeter(V2G) and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres, Aliment Pharmacol Ther, 50, 1214, 10.1111/apt.15529 Loo, 2018, Enhanced liver fibrosis score as a predictor of hepatocellular carcinoma, Clin Chem, 64, 1404, 10.1373/clinchem.2018.289108 Trembling, 2020, The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease, BMC Gastroenterol, 20, 104, 10.1186/s12876-020-01251-w Heistaro, 2008 Eddowes, 2019, Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1717, 10.1053/j.gastro.2019.01.042 Imajo, 2016, Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography, Gastroenterology, 150, 626, 10.1053/j.gastro.2015.11.048 Myers, 2012, Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients, Hepatology, 55, 199, 10.1002/hep.24624 Jamialahmadi, 2019, Measurement of liver stiffness with 2D-shear wave elastography (2D-SWE) in bariatric surgery candidates reveals acceptable diagnostic yield compared to liver biopsy, Obes Surg, 29, 2585, 10.1007/s11695-019-03889-2 Hagström, 2020, Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease, Gastroenterology, 158, 200, 10.1053/j.gastro.2019.09.008 Lichtinghagen, 2013, The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values, J Hepatol, 59, 236, 10.1016/j.jhep.2013.03.016 De Vincentis, 2022, A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores, Clin Gastroenterol Hepatol, 20, 658, 10.1016/j.cgh.2021.05.056